U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector transforms.
Recent Posts
- Consumer sentiment drops in March to 57.9, according to University of Michigan survey, worse than expected
- Military families have special tax breaks — but the rules can be tricky, experts say
- U.S. stock market loses $5 trillion in value in three weeks
- Tech’s 3-week sell-off, led by Tesla, wipes out $2.7 trillion in value from megacaps
- A pullback in this restaurant stock is overdone, Loop Capital says in upgrade